MedTrace Logo

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2014-08-13

Study results available
· View outcomes & findings →

Summary

This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.

Conditions

  • Cognitive Aging

Interventions

DRUG

Guanfacine

Guanfacine 0.1 mg po qhs

DRUG

Guanfacine

Guanfacine 0.5 mg po qhs

DRUG

Placebo

Placebo po qhs

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Christopher H van Dyck, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935493 on ClinicalTrials.gov